Ervo R, Faletti P, Magni S, Cavatorta F
Department of Nephrology and Dialysis, USL N.1, Liguria-Ventimiglia, Italy.
Nephron. 1992;61(3):371-2. doi: 10.1159/000186949.
We have studied a series of 43 patients--who were suffering from uremia, subject to hemodialysis treatment, resulting seronegative to the test for HBV and who had never been vaccinated before--considering the HBS antibody as seroconversion index. We subdivided our patients into three groups, according to the treatment employed. First group: French vaccine; 2nd group: French vaccine+thymopenthine; 3rd group: recombining DNA vaccine+thymopentine. From a statistical point of view, in the 3rd group we obtained a significant seroconversion in terms of patients, if compared with the other groups.
我们研究了一组43例患者，这些患者患有尿毒症，接受血液透析治疗，乙肝病毒检测呈血清阴性且此前从未接种过疫苗，将乙肝表面抗体作为血清转化指标。根据所采用的治疗方法，我们将患者分为三组。第一组：法国疫苗；第二组：法国疫苗+胸腺五肽；第三组：重组DNA疫苗+胸腺五肽。从统计学角度来看，与其他组相比，第三组在患者血清转化方面取得了显著效果。
